Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...

A panelist discusses how the shift from intravenous to oral AML therapies addresses significant quality-of-life concerns by eliminating the burden of spending 7 days per month in clinics for infusions ...

A pharmacogenetics score may help physicians predict which patients with acute myeloid leukemia are more likely to respond to ...

Is first-line treatment with polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A ...